VRCA Verrica Pharmaceuticals Inc.
USHealthcareAs of 2026-07-10 16:00
Why VRCA matters now
Verrica Pharmaceuticals Inc. (VRCA) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.26 with -4.13% on the session and $66.7M in market capitalization; recent performance reads 1-month +0.72% and YTD -32.25%.
The latest financial table shown here is Q1 2026, with revenue of $5.0M, net income of $-9.7M, and EPS of $-0.91. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -23.5%.
The latest indexable market news headline is "Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $13.00; recent insider activity includes Corcoran Gavin filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.74
P/S
1.61
EV/EBITDA
-3.59
DCF Value
$-21.13
FCF Yield
-23.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.5%
Operating Margin
-36.4%
Net Margin
-48.0%
ROE
-1136.5%
ROA
-46.0%
ROIC
-58.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $5.0M | $-9.7M | $-0.91 |
| Q4 2025 | $5.1M | $-8.1M | $-0.64 |
| FY 2025 | $35.6M | $-17.9M | $-1.68 |
| Q3 2025 | $14.3M | $-274.0K | $-0.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$13.25
Target (Median)
$13.00
Target Range
$10.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.49
Verrica Pharmaceuticals Inc. is a US-based pharmaceutical company dedicated to developing and commercializing therapeutic solutions for various skin diseases. Its primary investigational compound, VP-102, has successfully completed Phase II clinical trials for molluscum contagiosum and external genital warts, and is presently in Phase II development for common warts. Additionally, the company is advancing VP-103, a cantharidin-based product candidate, designed to treat plantar warts. Verrica maintains a strategic license and collaboration agreement with Torii Pharmaceutical Co., Ltd., focusing on the development and commercialization of its product candidates, including VP-102, for molluscum contagiosum and common warts in the Japanese market. Furthermore, a separate licensing agreement with Lytix Biopharma AS allows for the development and commercialization of LTX-315 for dermatological oncology applications. Verrica Pharmaceuticals Inc. was established in 2013 and has its headquarters in West Chester, Pennsylvania.